Education
About Us
Working with TipRanks
Follow Us
Aptorum Group Ltd (APM)
NASDAQ:APM
Top Page
Aptorum Group
(NASDAQ:APM)
Select Model
Select Model
Rating:41Neutral
Price Target:―
Aptorum Group's overall stock score of 41 reflects significant financial difficulties, with declining revenues and persistent losses as primary concerns. Technical analysis indicates bearish trends, and valuation metrics suggest the stock may be overvalued. The lack of earnings call and corporate events data leaves these areas unassessed.
Aptorum Group (APM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.57M
Dividend YieldN/A
Average Volume (3M)990.84K
Price to Earnings (P/E)49.7
Beta (1Y)0.88
Revenue GrowthN/A
EPS Growth-1979.68%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding5,346,823
10 Day Avg. Volume388,044
30 Day Avg. Volume990,836
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-12.82
Enterprise Value/Market Cap-0.13
Enterprise Value/Revenue-4.99
Enterprise Value/Gross Profit1.92
Enterprise Value/Ebitda0.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Aptorum Group Business Overview & Revenue Model
Company DescriptionAptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
How the Company Makes MoneyAptorum Group generates revenue primarily through the development and commercialization of pharmaceutical products. The company engages in the research and development of novel therapeutics, which, upon reaching successful clinical trial phases and receiving regulatory approvals, are either marketed directly or licensed to larger pharmaceutical companies that handle distribution. Licensing agreements and partnerships with other biotech firms and research institutions are significant contributors to its revenue, allowing Aptorum Group to leverage external expertise and resources to enhance its drug development pipeline. Additionally, Aptorum explores revenue generation through its healthcare consumer products segment, which involves the sale of non-pharmaceutical products that align with its core focus on health and wellness.
Aptorum Group Financial Statement Overview
Summary
Aptorum Group faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. While debt management has improved slightly, the company's profitability and cash generation remain concerning. Continued operational losses and reliance on financing suggest potential liquidity risks.Income Statement
The company shows declining revenue over the years with a significant revenue drop from 2022 to 2023. Gross profit margins are minimal, indicating challenges in covering costs. Net income remains negative, reflecting ongoing operational losses.25
Negative
Balance Sheet
The balance sheet indicates a reduction in total debt over the recent years, improving the debt-to-equity ratio. However, the equity ratio has decreased due to reducing stockholders' equity, which may indicate financial distress or poor returns on equity investments.50
Neutral
Cash Flow
Cash flow from operations remains negative, indicating cash burn. Free cash flow is consistently negative, suggesting the company struggles to generate cash after expenses. There is some improvement in financing activities, showing reliance on external funding.30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 431.38K | 0.00 | 431.38K | 1.30M | 1.54M | 911.51K |
| Gross Profit | -1.12M | -255.00K | 10.57K | 80.06K | 81.85K | -104.00K |
| EBITDA | -3.10M | -3.76M | -3.09M | -10.32M | -25.83M | 6.50M |
| Net Income | -2.83M | -4.27M | -2.83M | -9.80M | -25.05M | 7.07M |
Balance Sheet | ||||||
| Total Assets | 20.64M | 16.13M | 20.64M | 20.87M | 21.91M | 44.23M |
| Cash, Cash Equivalents and Short-Term Investments | 2.01M | 874.24K | 2.01M | 1.99M | 8.50M | 31.88M |
| Total Debt | 3.28M | 3.35M | 3.28M | 6.85M | 217.17K | 2.69M |
| Total Liabilities | 5.26M | 4.35M | 5.26M | 13.03M | 4.40M | 6.08M |
| Stockholders Equity | 24.85M | 21.13M | 24.85M | 15.71M | 23.61M | 41.83M |
Cash Flow | ||||||
| Free Cash Flow | -7.78M | -1.19M | -7.73M | -12.51M | -14.79M | -16.09M |
| Operating Cash Flow | -7.78M | -1.19M | -7.72M | -12.32M | -14.65M | -15.93M |
| Investing Cash Flow | 624.77K | 58.62K | 624.77K | 2.44M | 16.51M | 1.84M |
| Financing Cash Flow | 4.15M | 1.43K | 4.09M | 6.63M | 2.78M | 12.42M |
Aptorum Group Technical Analysis
Positive
2.32
Price Trends
1.83
Positive
1.48
Positive
1.27
Positive
Market Momentum
0.10
Negative
54.31
Neutral
63.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APM, the sentiment is Positive. The current price of 2.32 is above the 20-day moving average (MA) of 1.93, above the 50-day MA of 1.83, and above the 200-day MA of 1.27, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 54.31 is Neutral, neither overbought nor oversold. The STOCH value of 63.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APM.
Aptorum Group Risk Analysis
Aptorum Group disclosed 73 risk factors in its most recent earnings report. Aptorum Group reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aptorum Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $13.30M | ― | -238.26% | ― | -57.69% | 63.76% | |
41 Neutral | $16.57M | 49.73 | -9.02% | ― | ― | -1979.68% | |
40 Underperform | $7.16M | ― | 234.90% | ― | ― | 47.54% | |
34 Underperform | $2.51M | ― | -181.99% | ― | ― | 46.96% |
* Healthcare Sector Average
APM
Aptorum Group
2.09
0.39
22.94%
BCLI
Brainstorm Cell Therapeutics
0.70
-1.45
-67.44%
GTBP
GT Biopharma
0.75
-1.33
-63.94%
LYRA
Lyra Therapeutics
7.59
-3.34
-30.56%
CDT
Conduit Pharmaceuticals
0.77
-158.98
-99.52%
LIPO
Lipella Pharmaceuticals, Inc.
0.61
-2.66
-81.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.